New drug HMPL-A251 targets Hard-to-Treat HER2 cancers in early trial
NCT ID NCT07228247
First seen Nov 15, 2025 · Last updated May 21, 2026 · Updated 19 times
Summary
This study tests a new drug called HMPL-A251 in adults with advanced or metastatic solid tumors that have a protein called HER2. The main goals are to find a safe dose and see if the drug can shrink tumors. About 147 participants will receive the drug, and researchers will monitor side effects and how well the cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS, ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
BRCR Global
NOT_YET_RECRUITINGPlantation, Florida, 33322, United States
Contact
-
Cleveland Clinic Taussig Cancer Center
NOT_YET_RECRUITINGCleveland, Ohio, 44195, United States
Contact
-
Fujian Cancer Hospital
NOT_YET_RECRUITINGFujian, China
Contact
-
Henan Cancer Hospital
NOT_YET_RECRUITINGZhengzhou, China
Contact
-
Hunan Cancer Hospital
NOT_YET_RECRUITINGChangsha, China
Contact
-
Memorial Sloan Kettering Cancer Center
NOT_YET_RECRUITINGNew York, New York, 10065, United States
Contact
-
Peking University First Hospital
NOT_YET_RECRUITINGBeijing, China
Contact
-
SCRI HealthONE
NOT_YET_RECRUITINGDenver, Colorado, 80218, United States
Contact
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Vanderbilt University Medical Center
NOT_YET_RECRUITINGNashville, Tennessee, 37232, United States
Contact
Conditions
Explore the condition pages connected to this study.